All in all, the findings lay the foundation for the development of drugs that boost S1P to treat or prevent coronary artery disease, the researchers concluded. More information: Onorina L. Manzo ...

Researchers investigated the potential association between plasma apolipoprotein M (APOM) levels and the risk of adverse ...

Cenerimod is a novel oral S1P1 receptor modulator with potential to be a first- or best-in-class therapy for multiple ...

In its first phase 3 readout, oral S1P receptor modulator etrasimod met its objectives in patients with moderately-to-severely active ulcerative colitis, who had previously failed or were ...

Orally-active S1P agonist Zeposia (ozanimod) has been submitted to the FDA as a treatment for adults with moderately to severely active ulcerative colitis (UC), with a decision from the US ...